Compare Sezzle Inc (SEZL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs BIO-TECHNE Corp — how do they compare? Sezzle Inc trades at $178.82 (market cap $5.78B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| SEZL | TECH | |
|---|---|---|
Market Cap | $5.78B | $11.16B |
Sector | Technology | Health |
52-Week High | $188.55 | $72.12 |
52-Week Low | $50.97 | $43.31 |
Enterprise Value | $5.80B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sezzle (SEZL) trades at $171.76, down 1.67% today but maintaining strong momentum with consistent earnings beats and bullish technical indicators. The stock shows robust fundamentals with 30.83% net income margin and 91.95% ROE, though valuations remain elevated at P/E 41.72. Recent news highlights product expansion and strong Q1 2026 results, with the company scheduled to report Q2 earnings on August 6, 2026.
Outlook remains positive given earnings momentum and analyst consensus, but high valuation multiples and competitive fintech landscape pose risks. The stock trades above the $162 consensus target, suggesting near-term consolidation potential before potential upward revisions post-earnings.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
